Nurse Practitioner in Saranac, MI Accepting Medicare
3 Nurse Practitioner nurses found. Showing 1 - 3
 Jennifer Lynn Moilanen, NP-C Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 107 N Bridge St, Saranac, MI 48881 Phone: 616-642-9408 Fax: 616-642-6940 |
Mrs. Laura Hillard, FNP-BC Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 4042 Misty Meadows Dr, Saranac, MI 48881 Phone: 517-819-7229 |
Marie Denise Johnson, NP-C Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 107 N Bridge St, Saranac, MI 48881 Phone: 616-642-9408 Fax: 616-642-6940 |
News Archive
Assurex Health announces release of new psychiatric pharmacogenomic test panel
Assurex Health today announced the release of GeneSight Psychotropic 2.0, its lead psychiatric pharmacogenomic test panel. This latest GeneSight Psychotropic version has been updated to include four additional medications that now cover a total of 36 of the most commonly prescribed psychotropic medications in the US.
New perspective on coronary disease thanks to ultrasound
Compared to other techniques, Intravascular Ultrasound (IVUS) is much better at monitoring the increase or decrease of atherosclerosis in the coronary arteries. Can the method even be used to predict the odds of a heart attack or other cardiovascular event? Studies indicate this may be the case, states Professor Clemens von Birgelen in his inaugural address at the University of Twente.
Also in Global Health News: WHO highlights health care-associated infections; Niger food shortages, health care workers; Latin American food security
The WHO on Thursday highlighted the importance of hand washing and other efforts to prevent health care-associated infections (HAIs), which affect millions of people annually, with developing countries carrying the greatest burden of such infections, CIDRAP News reports.
ChemGenex agrees with FDA on potential regulatory path to progress OMAPRO for CML
ChemGenex Pharmaceuticals Limited announced today it has agreed with the U.S. Food and Drug Administration (FDA) on a potential regulatory path to progress OMAPRO™ (omacetaxine mepesuccinate) for the treatment of patients with Chronic Myeloid Leukemia (CML).
Partnerships, additional funding allow for expansion of PEPFAR to combat cervical cancer
In this post in the Public Health Institute's "Dialogue4Health" blog, Jeffrey Meer, director of PHI's Washington-based advocacy on global health, writes that "a significant expansion of PEPFAR's existing work to combat cervical cancer" through a partnership with the George W. Bush Institute known as Pink Ribbon Red Ribbon (PRRR); a 50 percent increase in the U.S. government's "commitment to screen and treat for this type of cancer from $20 million over five years to $30 million"; and additional funding from Susan G. Komen for the Cure "to expand breast cancer awareness and prevention among the same target population of women receiving care at PEPFAR-funded HIV service sites" has allowed "the wonderfully robust PEPFAR prevention and treatment platform, considered one of the great global health achievements in recent times, to be made available to a whole new type of prevention - in this case for a non-communicable disease (NCD)."
› Verified 6 days ago